1. Disease Information

1.1 Overview (current understanding)

KS is a rare congenital disorder characterized by hypogonadotropic hypogonadism plus impaired sense of smell, with broad phenotypic heterogeneity (reproductive and non-reproductive anomalies). (laitinen2011incidencephenotypicfeatures pages 1-2, zak2024kallmannsyndromecausessymptoms pages 1-5)

Key mechanistic definition: KS “results from disturbed intrauterine migration of gonadotropin-releasing hormone (GnRH) neurons from the olfactory placode to the hypothalamus.” (laitinen2011incidencephenotypicfeatures pages 1-2)

1.2 Key identifiers (available in retrieved sources)

• OMIM (MIM): KS is explicitly listed as MIM#147950. (laitinen2011incidencephenotypicfeatures pages 1-2)
• Related OMIM: hypogonadotropic hypogonadism is cited as MIM#146110 in the same source. (laitinen2011incidencephenotypicfeatures pages 1-2)
• ICD-10 (as used in Finnish discharge register ascertainment): hypogonadotropic hypogonadism E23.04 (and ICD-9 253.4). (laitinen2011incidencephenotypicfeatures pages 1-2)

Not found in the retrieved evidence snippets (therefore cannot be asserted here with citations): Orphanet ORPHA code, MeSH ID, MONDO ID, and ICD-11 code for KS specifically. (laitinen2011incidencephenotypicfeatures pages 1-2, meczekalski2013kallmannsyndromein pages 1-2)

1.3 Synonyms and alternative names

A women-focused KS review explicitly lists alternative names/synonyms: “de Morsier syndrome”, “dysplasia olfactogenitalis”, and “familial hypogonadism with anosmia”. (meczekalski2013kallmannsyndromein pages 1-2)

1.4 Evidence provenance

Most information in this report is derived from aggregated disease-level resources: population-based epidemiology (Finland), cohort sequencing studies, and clinical genetics reviews—not from EHR-only sources. (laitinen2011incidencephenotypicfeatures pages 1-2, kałuzna2021defectsingnrh pages 1-2, sayed2023paneltestingfor pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: genetic defects affecting GnRH neuron development/migration and/or hypothalamic–pituitary signaling, producing congenital GnRH deficiency and associated olfactory defects. (laitinen2011incidencephenotypicfeatures pages 1-2, kałuzna2021defectsingnrh pages 1-2)

2.2 Risk factors

• Genetic: pathogenic/likely pathogenic variants in multiple genes (see Section 4). KS is “genetically heterogeneous,” with multiple inheritance modes (X-linked, autosomal dominant/recessive, and oligogenic). (laitinen2011incidencephenotypicfeatures pages 1-2, sayed2023paneltestingfor pages 1-2)
• Non-genetic/environmental: no specific environmental risk factors were identified in the retrieved evidence; KS is generally treated as primarily genetic/developmental in the cited sources. (laitinen2011incidencephenotypicfeatures pages 1-2, sayed2023paneltestingfor pages 1-2)

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved evidence. (laitinen2011incidencephenotypicfeatures pages 1-2, sayed2023paneltestingfor pages 1-2)

2.4 Gene–environment interactions

No specific gene–environment interaction evidence was identified in the retrieved texts. (laitinen2011incidencephenotypicfeatures pages 1-2, sayed2023paneltestingfor pages 1-2)

3. Phenotypes

KS has a wide phenotype spectrum including reproductive, olfactory, congenital anomaly, neurologic, and psychosocial manifestations. (laitinen2011incidencephenotypicfeatures pages 1-2, zak2024kallmannsyndromecausessymptoms pages 1-5)

Table: This table summarizes the core reproductive, olfactory, neurologic, congenital, psychological, and laboratory phenotypes reported in Kallmann syndrome, with suggested HPO mappings and evidence-linked notes. It is useful for structured disease knowledge-base curation and phenotype annotation.

3.1 Phenotypic spectrum and timing

• Neonatal/infancy (males): cryptorchidism and micropenis may be early “red flags” for CHH/KS. (sayed2023paneltestingfor pages 1-2, liu2022advancesingenetic pages 1-2)
• Adolescence: absent or incomplete puberty and delayed sexual maturation are common triggers for diagnosis. (zak2024kallmannsyndromecausessymptomsa pages 1-5, meczekalski2013kallmannsyndromein pages 3-4)
• Adulthood: infertility/subfertility becomes prominent if untreated; chronic hypogonadism contributes to low bone mineral density and fracture risk. (meczekalski2013kallmannsyndromein pages 3-4, zak2024kallmannsyndromecausessymptoms pages 1-5)

3.2 Frequency data and cohort statistics (available)

• Finnish epidemiology/ascertainment: KS minimal incidence 1:48,000 overall (sex-stratified in Section 9). (laitinen2011incidencephenotypicfeatures pages 1-2)
• Genetic diagnostic yield in a KS cohort (Poland, panel sequencing): P/LP variants detected in 43.5% (20/46) and oligogenic P/LP defects in 26% (12/46). (kałuzna2021defectsingnrh pages 1-2)

For specific non-reproductive phenotype frequencies (e.g., renal agenesis rate, mirror movements rate), the retrieved evidence identifies these features but does not provide consistent percentages in the snippets available; therefore only qualitative assertions are provided. (laitinen2011incidencephenotypicfeatures pages 1-2, zak2024kallmannsyndromecausessymptoms pages 5-8)

4. Genetic / Molecular Information

4.1 Causal genes (representative, non-exhaustive)

Multiple genes are implicated, including ANOS1 (KAL1), FGFR1, FGF8, PROK2, PROKR2, CHD7, WDR11, SOX10, SEMA3A, among others; genetic heterogeneity and incomplete penetrance are emphasized across sources. (laitinen2011incidencephenotypicfeatures pages 1-2, sayed2023paneltestingfor pages 1-2, he2023clinicalmanifestationsgenetic pages 1-2, zak2024kallmannsyndromecausessymptoms pages 1-5)

Table: This table summarizes the main genes implicated in Kallmann syndrome, their typical inheritance patterns, and the developmental mechanisms linking them to GnRH deficiency and olfactory dysfunction. It is useful for rapid comparison of core KS genes while highlighting oligogenicity and incomplete penetrance.

4.2 Pathogenic variant types and classification practices

• A 2023 KS mutation study reported identification of novel ANOS1 variants including splice-altering mutations validated by functional splicing assay, and FGFR1 variants including frameshift and pathogenic CNV deletions, interpreted under ACMG/ClinGen standards. (zak2024kallmannsyndromecausessymptomsa pages 1-5)
• A 2023 sporadic IHH/KS cohort explicitly classified variants according to ACMG-AMP guidelines and reported a novel likely pathogenic SOX10 splice variant (c.429–1G>C) in a KS patient. (he2023clinicalmanifestationsgenetic pages 1-2)

4.3 Oligogenicity and diagnostic yield (recent emphasis)

• A KS cohort sequencing study found “The prevalence of oligogenic P/LP defects…was 26% (12/46)” and P/LP variants in “43.5%.” (kałuzna2021defectsingnrh pages 1-2)
• A CHH genetic testing perspective emphasizes that CHH/KS genetics includes “di- and oligogenic, as well as classic monogenic, inheritance and incomplete penetrance,” and notes a curated 14-gene panel adopted in the UK NHS Genomic Medicine Service for CHH molecular diagnosis. (sayed2023paneltestingfor pages 1-2)

4.4 Epigenetic information

Direct epigenetic mechanisms (methylation/histone marks) were not identified in the retrieved evidence; however, chromatin remodeling genes (e.g., CHD7) can contribute to KS/CHH phenotypes. (sayed2023paneltestingfor pages 1-2, he2023clinicalmanifestationsgenetic pages 1-2)

4.5 Chromosomal/structural abnormalities

A structural defect affecting a long noncoding RNA was described: a KS patient with a balanced translocation implicating RMST. The abstract concludes: “A novel deletion in RMST implicates the loss of function of a lncRNA as a unique cause of KS and suggests it plays a critical role in the ontogeny of GnRH neurons and puberty.” (zak2024kallmannsyndromecausessymptomsa pages 1-5)

5. Environmental Information

No specific toxins, lifestyle exposures, or infectious agents were identified as contributors in the retrieved KS-focused evidence; the disorder is predominantly presented as genetic/developmental. (laitinen2011incidencephenotypicfeatures pages 1-2, sayed2023paneltestingfor pages 1-2)

6. Mechanism / Pathophysiology

6.1 Causal chain (current consensus in retrieved sources)

1. Upstream developmental defect: genetic disruptions in pathways controlling olfactory system development and GnRH neuron ontogeny/migration. (laitinen2011incidencephenotypicfeatures pages 1-2, kałuzna2021defectsingnrh pages 1-2)
2. Key developmental event: GnRH neurons normally migrate from the olfactory placode/nasal region to the hypothalamus; KS arises when this is disturbed. (laitinen2011incidencephenotypicfeatures pages 1-2, kałuzna2021defectsingnrh pages 1-2)
3. Downstream endocrine consequence: impaired GnRH pulsatility → low/inappropriately normal LH/FSH → hypogonadism, absent puberty, infertility. (he2023clinicalmanifestationsgenetic pages 1-2, zak2024kallmannsyndromecausessymptomsa pages 5-8)
4. Parallel olfactory phenotype: olfactory bulb/tract hypoplasia or agenesis may accompany the GnRH neuronal defect (e.g., MRI findings). (zak2024kallmannsyndromecausessymptomsa pages 5-8, zak2024kallmannsyndromecausessymptoms pages 5-8)

6.2 Molecular/cellular processes and example pathway anchors

• GnRH neuronal migration and axon guidance: A KS genetics study describes GnRH neurons originating in the nasal region and migrating toward the brain, consistent with shared developmental origins of the olfactory and reproductive axes. (kałuzna2021defectsingnrh pages 1-2)
• PROKR2 biology: Review-level mechanistic evidence links PROKR2 loss to abnormal olfactory bulb formation and GnRH neuron migration; the abstract states: “Mice lacking Prokr2 have been shown to present abnormal olfactory bulb formation as well as defects in GnRH neuron migration. Patients carrying mutations in PROKR2 typically present hypogonadotropic hypogonadism, anosmia/hyposmia or Kallmann Syndrome.” (zak2024kallmannsyndromecausessymptomsa pages 1-5)

6.3 Suggested ontology terms

• GO biological processes (suggested):
• GnRH neuron migration/development (e.g., neuron migration; axon guidance; olfactory bulb development; regulation of GnRH secretion)
• Cell types (CL, suggested):
• Gonadotropin-releasing hormone neuron; olfactory ensheathing cell (supporting GnRH axon pathfinding); neural crest cell (as implicated in RMST/iPSC-NCC modeling) (kałuzna2021defectsingnrh pages 1-2, zak2024kallmannsyndromecausessymptomsa pages 1-5)

7. Anatomical Structures Affected

7.1 Organ and system level

• Hypothalamic–pituitary–gonadal axis (endocrine/reproductive) leading to hypogonadism and infertility. (he2023clinicalmanifestationsgenetic pages 1-2, sayed2023paneltestingfor pages 1-2)
• Olfactory system (olfactory bulbs/tracts), often with structural or functional deficits. (zak2024kallmannsyndromecausessymptomsa pages 5-8, zak2024kallmannsyndromecausessymptoms pages 5-8)

7.2 Tissue and cell level (suggested)

• Neuroendocrine neurons: GnRH neurons (hypothalamic). (laitinen2011incidencephenotypicfeatures pages 1-2)
• Olfactory pathway-associated cells: olfactory-related guidance/support (e.g., olfactory ensheathing cells, based on migration framework). (kałuzna2021defectsingnrh pages 1-2)

7.3 Subcellular level

No consistent subcellular compartment pathology (e.g., mitochondria/ER) is specified in the retrieved evidence.

8. Temporal Development

• Onset: congenital, but diagnosis commonly occurs in adolescence; neonatal male signs may enable earlier recognition. (zak2024kallmannsyndromecausessymptomsa pages 1-5, sayed2023paneltestingfor pages 1-2)
• Course: chronic lifelong without treatment; phenotypic severity ranges from severe HH with absent puberty to partial puberty, and “reversal of hypogonadotropism later in life” is possible in some cases. (laitinen2011incidencephenotypicfeatures pages 1-2)
• Reversal: a recent review states spontaneous recovery occurs in “approximately 10–20%,” though details are not in the snippet. (zak2024kallmannsyndromecausessymptoms pages 5-8)

9. Inheritance and Population

9.1 Epidemiology (recently cited benchmark)

A Finnish population-based ascertainment study reports: “The minimal incidence estimate of KS in Finland was 1:48 000, with clear difference between males (1:30 000) and females (1:125 000).” (laitinen2011incidencephenotypicfeatures pages 1-2)

A key visual summary of clinical features and genotypes appears in Table 1 of this Finnish paper (cropped). (laitinen2011incidencephenotypicfeatures media a022cd77)

9.2 Inheritance patterns

• Family patterns include X-linked recessive, autosomal dominant, autosomal recessive, and oligogenic inheritance. (laitinen2011incidencephenotypicfeatures pages 1-2)
• Clinical genetics perspective underscores incomplete penetrance and the need for careful interpretation of genetic results in panels. (sayed2023paneltestingfor pages 1-2)

10. Diagnostics

10.1 Clinical and laboratory testing

• Hormones: KS commonly shows very low gonadotropins; one review states: “Patients of both sexes with KS exhibit very low plasma levels of gonadotropins, including FSH, LH and inhibin B.” (zak2024kallmannsyndromecausessymptomsa pages 5-8)
• Mini-puberty window (infants): highlighted as a diagnostic opportunity (1–3 months) to assess congenital GnRH deficiency. (zak2024kallmannsyndromecausessymptomsa pages 5-8)

10.2 Olfactory testing and imaging

• Formal olfactory assessment: UPSIT thresholds were used in Finnish ascertainment (anosmia <5th percentile for age). (laitinen2011incidencephenotypicfeatures pages 1-2)
• MRI: reviews emphasize MRI findings such as unilateral/bilateral agenesis of olfactory bulbs/tracts in KS patients, supporting diagnosis and phenotyping. (zak2024kallmannsyndromecausessymptomsa pages 5-8, zak2024kallmannsyndromecausessymptoms pages 5-8)

10.3 Genetic testing (real-world implementation)

• Modern practice increasingly uses NGS-based panels/WES due to genetic heterogeneity. (he2023clinicalmanifestationsgenetic pages 1-2, sayed2023paneltestingfor pages 1-2)
• In the UK NHS Genomic Medicine Service, a curated 14-gene CHH diagnostic panel has been adopted (review report). (sayed2023paneltestingfor pages 1-2)

10.4 Differential diagnosis

Reviews highlight differentiation from constitutional delay of growth and puberty (CDGP), CHARGE syndrome, tumors causing acquired HH, and functional hypogonadotropic hypogonadism. (zak2024kallmannsyndromecausessymptomsa pages 5-8, zak2024kallmannsyndromecausessymptoms pages 5-8)

11. Outcome / Prognosis

• Fertility: CHH/KS is considered treatable for fertility; one authoritative review states fertility “can be restored in approximately 75% of men and women” with appropriate therapy. (sayed2023paneltestingfor pages 1-2)
• Bone health: untreated KS is associated with osteoporosis/osteopenia and increased fracture risk (secondary to chronic hypogonadism). (meczekalski2013kallmannsyndromein pages 3-4)
• Psychosocial burden: reviews note substantial psychological morbidity and emphasize psychological support as part of management. (zak2024kallmannsyndromecausessymptomsa pages 5-8, zak2024kallmannsyndromecausessymptomsa pages 8-13)

Mortality/life expectancy statistics specific to KS were not identified in the retrieved evidence snippets.

12. Treatment

12.1 Hormone replacement (puberty induction / maintenance)

• Males: testosterone replacement is used to induce/maintain virilization and secondary sexual characteristics. (zak2024kallmannsyndromecausessymptoms pages 5-8, sayed2023paneltestingfor pages 1-2)
• Females: 17β-estradiol with later addition of progesterone (or estrogen–progestin regimens) to induce/maintain feminization and protect endometrium. (zak2024kallmannsyndromecausessymptoms pages 5-8, meczekalski2013kallmannsyndromein pages 3-4)

12.2 Fertility induction

• Pulsatile GnRH or gonadotropin therapy (e.g., hCG/FSH-based regimens) are used for fertility induction in adults (both sexes). (zak2024kallmannsyndromecausessymptoms pages 5-8)
• Treatment success for fertility restoration is summarized at population level as ~75% in the CHH panel-testing review. (sayed2023paneltestingfor pages 1-2)

12.3 Surgical/interventional and supportive care

• Cryptorchidism repair is recommended early in infancy (review suggests 6–12 months). (zak2024kallmannsyndromecausessymptoms pages 5-8)
• Psychological support is repeatedly recommended given psychosocial impacts. (zak2024kallmannsyndromecausessymptomsa pages 1-5, zak2024kallmannsyndromecausessymptomsa pages 5-8)

12.4 Experimental/advanced therapeutics

No KS-specific gene therapy or RNA therapy clinical trials were identified in retrieved evidence.

12.5 Suggested MAXO terms (examples)

• Hormone replacement therapy (sex steroid replacement)
• Gonadotropin therapy
• Pulsatile GnRH therapy
• Orchidopexy (cryptorchidism repair)

13. Prevention

Primary prevention is not currently established for KS (congenital genetic/developmental). However, reproductive genetic options are discussed in a genetic diagnosis review, including prenatal diagnosis and preimplantation genetic testing (PGT) to reduce transmission risk in affected families. (liu2022advancesingenetic pages 1-2)

14. Other Species / Natural Disease

No naturally occurring veterinary analogs were identified in the retrieved evidence.

15. Model Organisms

Mouse models are used to support mechanism. For example, Prokr2 loss in mice is associated with “abnormal olfactory bulb formation” and “defects in GnRH neuron migration,” paralleling the human KS phenotype spectrum. (zak2024kallmannsyndromecausessymptomsa pages 1-5)

Recent developments and latest research emphasis (2023–2024)

1. Clinical deployment of curated genetic panels (UK NHS): A 2023 European Journal of Human Genetics review reports a curated 14-gene panel for CHH diagnosis within the NHS Genomic Medicine Service and highlights pitfalls/benefits in real-world endocrine diagnostics, stressing oligogenicity and incomplete penetrance. Publication date: Dec 2023; URL: https://doi.org/10.1038/s41431-022-01261-0 (sayed2023paneltestingfor pages 1-2)
2. Oligogenicity quantified in KS cohort sequencing: A KS cohort NGS study reports 26% oligogenic P/LP defects and 43.5% P/LP detection (Genes, 2021; still widely relevant as quantification). (kałuzna2021defectsingnrh pages 1-2)
3. 2024 literature synthesis: A 2024 KS review summarizes contemporary diagnostic workup (including mini-puberty, olfactory testing, MRI), modern genetics, and treatment approaches including reported reversal (10–20%). (zak2024kallmannsyndromecausessymptomsa pages 1-5, zak2024kallmannsyndromecausessymptoms pages 5-8)

Key visual evidence

A cropped Table 1 from the Finland epidemiology/genetics study summarizes clinical and molecular genetic features across KS probands (supporting phenotypic heterogeneity and genotype-phenotype mapping). (laitinen2011incidencephenotypicfeatures media a022cd77)

Limitations of this evidence package

• Standard ontology identifiers (MONDO, Orphanet ORPHA, MeSH ID, ICD-11 for KS) were not present in the retrieved full-text snippets and therefore are not asserted here.
• Several clinically important phenotype frequencies (e.g., renal agenesis %, mirror movements %) are identified qualitatively but were not numerically extractable from the available snippets.

References

1. (laitinen2011incidencephenotypicfeatures pages 1-2): Eeva-Maria Laitinen, Kirsi Vaaralahti, Johanna Tommiska, Elina Eklund, Mari Tervaniemi, Leena Valanne, and Taneli Raivio. Incidence, phenotypic features and molecular genetics of kallmann syndrome in finland. Orphanet Journal of Rare Diseases, 6:41-41, Jun 2011. URL: https://doi.org/10.1186/1750-1172-6-41, doi:10.1186/1750-1172-6-41. This article has 244 citations and is from a peer-reviewed journal.

2. (zak2024kallmannsyndromecausessymptoms pages 1-5): N Żak. Kallmann syndrome-causes, symptoms, treatment-review of literature. Unknown journal, 2024.

3. (meczekalski2013kallmannsyndromein pages 3-4): Blazej Meczekalski, Agnieszka Podfigurna-Stopa, Roman Smolarczyk, Krzysztof Katulski, and Andrea R. Genazzani. Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecological Endocrinology, 29:296-300, Mar 2013. URL: https://doi.org/10.3109/09513590.2012.752459, doi:10.3109/09513590.2012.752459. This article has 46 citations and is from a peer-reviewed journal.

4. (zak2024kallmannsyndromecausessymptomsa pages 1-5): N Żak. Kallmann syndrome-causes, symptoms, treatment-review of literature. Unknown journal, 2024.

5. (meczekalski2013kallmannsyndromein pages 1-2): Blazej Meczekalski, Agnieszka Podfigurna-Stopa, Roman Smolarczyk, Krzysztof Katulski, and Andrea R. Genazzani. Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecological Endocrinology, 29:296-300, Mar 2013. URL: https://doi.org/10.3109/09513590.2012.752459, doi:10.3109/09513590.2012.752459. This article has 46 citations and is from a peer-reviewed journal.

6. (kałuzna2021defectsingnrh pages 1-2): Małgorzata Kałużna, Bartłomiej Budny, Michał Rabijewski, Jarosław Kałużny, Agnieszka Dubiel, Małgorzata Trofimiuk-Müldner, Elżbieta Wrotkowska, Alicja Hubalewska-Dydejczyk, Marek Ruchała, and Katarzyna Ziemnicka. Defects in gnrh neuron migration/development and hypothalamic-pituitary signaling impact clinical variability of kallmann syndrome. Genes, 12:868, Jun 2021. URL: https://doi.org/10.3390/genes12060868, doi:10.3390/genes12060868. This article has 19 citations.

7. (sayed2023paneltestingfor pages 1-2): Yasmin Al Sayed and Sasha R. Howard. Panel testing for the molecular genetic diagnosis of congenital hypogonadotropic hypogonadism – a clinical perspective. European Journal of Human Genetics, 31:387-394, Dec 2023. URL: https://doi.org/10.1038/s41431-022-01261-0, doi:10.1038/s41431-022-01261-0. This article has 35 citations and is from a domain leading peer-reviewed journal.

8. (liu2022advancesingenetic pages 1-2): Yujun Liu and Xu Zhi. Advances in genetic diagnosis of kallmann syndrome and genetic interruption. Reproductive Sciences, 29:1697-1709, Jul 2022. URL: https://doi.org/10.1007/s43032-021-00638-8, doi:10.1007/s43032-021-00638-8. This article has 42 citations and is from a peer-reviewed journal.

9. (zak2024kallmannsyndromecausessymptoms pages 5-8): N Żak. Kallmann syndrome-causes, symptoms, treatment-review of literature. Unknown journal, 2024.

10. (he2023clinicalmanifestationsgenetic pages 1-2): Dongye He, Hailing Sun, Mei Zhang, Yanying Li, Fupeng Liu, Yanhong Zhang, Mingming He, and Bo Ban. Clinical manifestations, genetic variants and therapeutic evaluation in sporadic chinese patients with idiopathic hypogonadotropic hypogonadism. International Journal of General Medicine, 16:4429-4439, Sep 2023. URL: https://doi.org/10.2147/ijgm.s430904, doi:10.2147/ijgm.s430904. This article has 1 citations.

11. (zak2024kallmannsyndromecausessymptomsa pages 5-8): N Żak. Kallmann syndrome-causes, symptoms, treatment-review of literature. Unknown journal, 2024.

12. (zak2024kallmannsyndromecausessymptomsa pages 8-13): N Żak. Kallmann syndrome-causes, symptoms, treatment-review of literature. Unknown journal, 2024.

13. (stamou2018kallmannsyndromephenotype pages 1-3): Maria I. Stamou and Neoklis A. Georgopoulos. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Sep 2018. URL: https://doi.org/10.1016/j.metabol.2017.10.012, doi:10.1016/j.metabol.2017.10.012. This article has 222 citations.

14. (laitinen2011incidencephenotypicfeatures media a022cd77): Eeva-Maria Laitinen, Kirsi Vaaralahti, Johanna Tommiska, Elina Eklund, Mari Tervaniemi, Leena Valanne, and Taneli Raivio. Incidence, phenotypic features and molecular genetics of kallmann syndrome in finland. Orphanet Journal of Rare Diseases, 6:41-41, Jun 2011. URL: https://doi.org/10.1186/1750-1172-6-41, doi:10.1186/1750-1172-6-41. This article has 244 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02